Descripción del proyecto
Reducción de la resistencia a un tratamiento importante para la tuberculosis
Las enfermedades infecciosas son provocadas por bacterias, virus, hongos y parásitos. Existen vacunas para prevenir las infecciones o medicamentos para matar a los organismos, pero un número cada vez mayor de organismos están volviéndose resistentes a los tratamientos. La tuberculosis (TB) es causada por las bacterias «Mycobacterium tuberculosis». En muchos casos, estas bacterias son resistentes a múltiples fármacos y, algunas veces, con resultados letales. El proyecto TRIC-TB, financiado con fondos europeos, está explorando una forma prometedora de mejorar la eficacia del tratamiento de la TB multirresistente. Centrándose en recuperar la sensibilidad a una línea de tratamiento existente, los científicos esperan mejorar los resultados en los pacientes independientemente del estado de resistencia inicial en el momento de la infección.
Objetivo
Tuberculosis (TB) is the world’s leading infectious disease. It killed 1.7 million people in 2016 and 10.4 million people developed active TB in the same year. In 2016, 480’000 of TB cases were multidrug-resistant (MDR-TB) and 9% percent of those cases are extensively drug-resistant (XDR), with mortality rates as high as 70%. Ethionamide (ETH) is a vital part of the WHO essential medicines list of 2nd-line TB therapy for MDR-TB, however, ETH suffers from significant levels of resistance and side effects at current dosing levels. BVL-GSK038 and BVL-GSK098 are proprietary to BioVersys/GlaxoSmithKline and have been developed through an extensive Lead Optimization program with collaborators from Lille University. Low doses of both compounds fully restore and “boost” the activity of ETH to rapidly kill Mycobacterium tuberculosis (Mtb) including MDR strains at significantly lower doses of ETH than previously reported, thus making MDR-TB sensitive to ETH once again. Through a comprehensive IND enabling package including in vitro and in vivo assessment of ETH with BVL-GSK038 and BVL-GSK098, including PK/PD, resistance development, safety, mechanism of action and synergistic studies with different drug compound combinations and then first in human clinical studies the consortium aims to:
i) Define the future placement of a boosted ETH (ETH + BVL-GSK038 or BVL-GSK098) in a universal TB treatment regimen, including overcoming MDR-TB with improved safety, time to cure and relapse rates;
Ultimately, we expect to identify a new and clinically proven TB regimen that leads to better patient outcomes independently of the starting resistance status of the TB infection. The TB and wider scientific communities will benefit from an improved understanding of ETH and the exploration of a novel class of therapeutic compounds acting on transcriptional modulators (BVL-GSK038 and BVL-GSK098).
Ámbito científico
Programa(s)
Tema(s)
Convocatoria de propuestas
H2020-JTI-IMI2-2018-16-single-stage
Consulte otros proyectos de esta convocatoriaRégimen de financiación
RIA - Research and Innovation actionCoordinador
4057 Basel
Suiza
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.